AstraZeneca announces 72% risk reduction in death or progression with novel breast cancer drug
Independent - 19-Sep-2021Enhertu improved overall survival rate in breast cancer patients
Join the club for FREE to access the whole archive and other member benefits.
Head of the Breast Cancer Program at IOB Institute of Oncology, Barcelona and Madrid
Head of the Breast Cancer Program at IOB Institute of Oncology, Quironsalud group, in both Madrid and Barcelona, founding pattern of Medica Scientia innovation Research (MedSIR), a company involved in the clinical development of clinical trials and Senior Clinical Investigator of the Breast Cancer Research Program at Vall d’Hebron Institute of Oncology. He is the author of more than 260 publications, especially about breast tumours and new drugs and more than 500 communications at different conferences. He actively participates in the development of numerous international clinical trials, and he is a member of the Scientific Committee of the European Society of Medical Oncology(ESMO), chair of the Committee for Breast Cancer, local therapy, ESMO 2020 and co-chair of the American Association for Cancer research (AACR) Annual Meeting 2021 Program Committee.
Visit website: https://oncology.medicinematters.com/advisory-board/javier-cortes/12004740
See also: IOB Institute of Oncology - Leading private cancer center in Europe
Details last updated 23-Sep-2021
Enhertu improved overall survival rate in breast cancer patients